Gut Bacteria and Weight Loss in Pancreatic Cancer Patients
Studies gut bacteria from pancreatic cancer patients with weight loss in mice.
Plain-language title generated from the registry record
Registry title: Microbiota and Pancreatic Cancer Cachexia
Key facts
- Where
- Geneva, SwitzerlandSee the site
Where in Switzerland
- Geneva University HospitalsGeneva, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Genton Graf Laurence
- Trial code
- NCT05606523
- Record updated
- 6 December 2024
- Original description
This monocentric study aims at evaluating the effects of fecal microbiota transplantation from newly diagnosed cachectic and non-cachectic pancreatic cancer patients, and healthy volunteers on several cachexia-related parameters of germ-free mice.Read full original descriptionShow less
Can Fecal Microbiota Transplantation of Cachectic Patients with Pancreas Cancer Impair Body Weight Gain in Germ-free Mice? the EXTRA Study
This monocentric study aims at evaluating the effects of fecal microbiota transplantation from newly diagnosed cachectic and non-cachectic pancreatic cancer patients, and healthy volunteers on several cachexia-related parameters of germ-free mice.
Inclusion: Patients with pancreatic cancer (n=12); ≥18 years and; Newly diagnosed of pancreatic adenocarcinoma (local or metastatic) and; Tube feeding or parenteral nutrition ≤ 14 days; Cachectic pancreatic cancer patients (n=6); Cachexia according to the Fearon criteria 1: involuntary weight loss >5% over the last 6 months, or any level of weight loss >2% and a BMI <20 kg/m2 or sarcopenia. Sarcopenia will be diagnosed by BIA (fat-free mass index is <17 kg/m2 in men and <15 kg/m2 in women) 81, and not by CT, as it is faster and can be performed at the bedside of the patient. Non-cachectic pancreatic cancer patients (n=6); Normal nutritional state: weight stability (± 2% of habitual weight) over the last 6 months, no anorexia before the diagnosis (appetite rating on a visual analogue scale of 100mm), no known impaired glucose tolerance; Healthy matched subjects (n=12); ≥18 years and; BMI between 18.5 and 30 kg/m2 and; Absence of chronic or acute disease and; Matching for gender and age (± 5 years) with an included pancreatic cancer patient.
Exclusion: Pancreatic adenocarcinoma already treated by chemo- or radiotherapy, or major surgery as duodenopancreatectomy or biliary diversion; Therapeutic antibiotics or immunosuppressive drugs (for instance glucocorticoids, cytostatics, antibodies) in the 30 days preceding the inclusion; Known rheumatologic or immunologic diseases; < 18 years or; Inability to give consent or; Insufficient knowledge of project language (French, German) or.